PMC:7096774 / 6602-7546 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"143","span":{"begin":167,"end":177},"obj":"Species"},{"id":"144","span":{"begin":280,"end":287},"obj":"Species"},{"id":"145","span":{"begin":298,"end":308},"obj":"Species"},{"id":"146","span":{"begin":592,"end":597},"obj":"Species"},{"id":"147","span":{"begin":384,"end":391},"obj":"Chemical"},{"id":"148","span":{"begin":542,"end":568},"obj":"Chemical"},{"id":"149","span":{"begin":570,"end":574},"obj":"Chemical"},{"id":"150","span":{"begin":249,"end":257},"obj":"Disease"},{"id":"151","span":{"begin":240,"end":242},"obj":"CellLine"}],"attributes":[{"id":"A143","pred":"tao:has_database_id","subj":"143","obj":"Tax:2697049"},{"id":"A144","pred":"tao:has_database_id","subj":"144","obj":"Tax:9606"},{"id":"A145","pred":"tao:has_database_id","subj":"145","obj":"Tax:2697049"},{"id":"A146","pred":"tao:has_database_id","subj":"146","obj":"Tax:9606"},{"id":"A147","pred":"tao:has_database_id","subj":"147","obj":"MESH:D000096"},{"id":"A150","pred":"tao:has_database_id","subj":"150","obj":"MESH:D007239"},{"id":"A151","pred":"tao:has_database_id","subj":"151","obj":"CVCL:4582"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Serum samples were collected from the index case on Days 4, 9, 10 and 20 from onset of the first symptoms (Figure 1). Presence of serum IgM and IgG antibodies against SARS-CoV-2 was analysed by immunofluorescence assays (IFA) based on Vero E6 cells infected with passage 4 of the patient’s isolate SARS-CoV-2/Finland/1/2020 virus and transferred onto microscope slides and fixed with acetone (Figure 2). Serum samples from the index case were serially diluted and incubated for 2 h for IgM and 30 min for IgG. Antibodies were visualised with fluorescein isothiocyanate (FITC)-conjugated anti-human IgM or IgG antibodies. While the antibodies were undetectable on Day 4 after onset of symptoms, IgG titres rose to 80 and 1,280 and IgM titres to 80 and 320 on Days 9 and 20, respectively (Table). Random serum samples from staff members of the University of Helsinki (n = 19) did not show specific binding at dilutions greater than 20 (Figure 2)."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T42","span":{"begin":0,"end":5},"obj":"Body_part"},{"id":"T43","span":{"begin":130,"end":135},"obj":"Body_part"},{"id":"T44","span":{"begin":136,"end":139},"obj":"Body_part"},{"id":"T45","span":{"begin":144,"end":147},"obj":"Body_part"},{"id":"T46","span":{"begin":243,"end":248},"obj":"Body_part"},{"id":"T47","span":{"begin":404,"end":409},"obj":"Body_part"},{"id":"T48","span":{"begin":486,"end":489},"obj":"Body_part"},{"id":"T49","span":{"begin":505,"end":508},"obj":"Body_part"},{"id":"T50","span":{"begin":510,"end":520},"obj":"Body_part"},{"id":"T51","span":{"begin":598,"end":601},"obj":"Body_part"},{"id":"T52","span":{"begin":605,"end":608},"obj":"Body_part"},{"id":"T53","span":{"begin":694,"end":697},"obj":"Body_part"},{"id":"T54","span":{"begin":730,"end":733},"obj":"Body_part"},{"id":"T55","span":{"begin":802,"end":807},"obj":"Body_part"}],"attributes":[{"id":"A42","pred":"fma_id","subj":"T42","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A43","pred":"fma_id","subj":"T43","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A44","pred":"fma_id","subj":"T44","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A45","pred":"fma_id","subj":"T45","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A46","pred":"fma_id","subj":"T46","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A47","pred":"fma_id","subj":"T47","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A48","pred":"fma_id","subj":"T48","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A49","pred":"fma_id","subj":"T49","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A50","pred":"fma_id","subj":"T50","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A51","pred":"fma_id","subj":"T51","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A52","pred":"fma_id","subj":"T52","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A53","pred":"fma_id","subj":"T53","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A54","pred":"fma_id","subj":"T54","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A55","pred":"fma_id","subj":"T55","obj":"http://purl.org/sig/ont/fma/fma63083"}],"text":"Serum samples were collected from the index case on Days 4, 9, 10 and 20 from onset of the first symptoms (Figure 1). Presence of serum IgM and IgG antibodies against SARS-CoV-2 was analysed by immunofluorescence assays (IFA) based on Vero E6 cells infected with passage 4 of the patient’s isolate SARS-CoV-2/Finland/1/2020 virus and transferred onto microscope slides and fixed with acetone (Figure 2). Serum samples from the index case were serially diluted and incubated for 2 h for IgM and 30 min for IgG. Antibodies were visualised with fluorescein isothiocyanate (FITC)-conjugated anti-human IgM or IgG antibodies. While the antibodies were undetectable on Day 4 after onset of symptoms, IgG titres rose to 80 and 1,280 and IgM titres to 80 and 320 on Days 9 and 20, respectively (Table). Random serum samples from staff members of the University of Helsinki (n = 19) did not show specific binding at dilutions greater than 20 (Figure 2)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T9","span":{"begin":0,"end":5},"obj":"Body_part"},{"id":"T10","span":{"begin":130,"end":135},"obj":"Body_part"},{"id":"T11","span":{"begin":404,"end":409},"obj":"Body_part"},{"id":"T12","span":{"begin":802,"end":807},"obj":"Body_part"}],"attributes":[{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A10","pred":"uberon_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A11","pred":"uberon_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"Serum samples were collected from the index case on Days 4, 9, 10 and 20 from onset of the first symptoms (Figure 1). Presence of serum IgM and IgG antibodies against SARS-CoV-2 was analysed by immunofluorescence assays (IFA) based on Vero E6 cells infected with passage 4 of the patient’s isolate SARS-CoV-2/Finland/1/2020 virus and transferred onto microscope slides and fixed with acetone (Figure 2). Serum samples from the index case were serially diluted and incubated for 2 h for IgM and 30 min for IgG. Antibodies were visualised with fluorescein isothiocyanate (FITC)-conjugated anti-human IgM or IgG antibodies. While the antibodies were undetectable on Day 4 after onset of symptoms, IgG titres rose to 80 and 1,280 and IgM titres to 80 and 320 on Days 9 and 20, respectively (Table). Random serum samples from staff members of the University of Helsinki (n = 19) did not show specific binding at dilutions greater than 20 (Figure 2)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T41","span":{"begin":167,"end":175},"obj":"Disease"},{"id":"T42","span":{"begin":298,"end":306},"obj":"Disease"}],"attributes":[{"id":"A41","pred":"mondo_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A42","pred":"mondo_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Serum samples were collected from the index case on Days 4, 9, 10 and 20 from onset of the first symptoms (Figure 1). Presence of serum IgM and IgG antibodies against SARS-CoV-2 was analysed by immunofluorescence assays (IFA) based on Vero E6 cells infected with passage 4 of the patient’s isolate SARS-CoV-2/Finland/1/2020 virus and transferred onto microscope slides and fixed with acetone (Figure 2). Serum samples from the index case were serially diluted and incubated for 2 h for IgM and 30 min for IgG. Antibodies were visualised with fluorescein isothiocyanate (FITC)-conjugated anti-human IgM or IgG antibodies. While the antibodies were undetectable on Day 4 after onset of symptoms, IgG titres rose to 80 and 1,280 and IgM titres to 80 and 320 on Days 9 and 20, respectively (Table). Random serum samples from staff members of the University of Helsinki (n = 19) did not show specific binding at dilutions greater than 20 (Figure 2)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T39","span":{"begin":235,"end":248},"obj":"http://purl.obolibrary.org/obo/CLO_0051719"},{"id":"T40","span":{"begin":324,"end":329},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T41","span":{"begin":592,"end":597},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"}],"text":"Serum samples were collected from the index case on Days 4, 9, 10 and 20 from onset of the first symptoms (Figure 1). Presence of serum IgM and IgG antibodies against SARS-CoV-2 was analysed by immunofluorescence assays (IFA) based on Vero E6 cells infected with passage 4 of the patient’s isolate SARS-CoV-2/Finland/1/2020 virus and transferred onto microscope slides and fixed with acetone (Figure 2). Serum samples from the index case were serially diluted and incubated for 2 h for IgM and 30 min for IgG. Antibodies were visualised with fluorescein isothiocyanate (FITC)-conjugated anti-human IgM or IgG antibodies. While the antibodies were undetectable on Day 4 after onset of symptoms, IgG titres rose to 80 and 1,280 and IgM titres to 80 and 320 on Days 9 and 20, respectively (Table). Random serum samples from staff members of the University of Helsinki (n = 19) did not show specific binding at dilutions greater than 20 (Figure 2)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T46","span":{"begin":384,"end":391},"obj":"Chemical"},{"id":"T47","span":{"begin":542,"end":568},"obj":"Chemical"},{"id":"T48","span":{"begin":542,"end":553},"obj":"Chemical"},{"id":"T49","span":{"begin":554,"end":568},"obj":"Chemical"},{"id":"T50","span":{"begin":570,"end":574},"obj":"Chemical"}],"attributes":[{"id":"A46","pred":"chebi_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/CHEBI_15347"},{"id":"A47","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_37926"},{"id":"A48","pred":"chebi_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/CHEBI_31624"},{"id":"A49","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_52221"},{"id":"A50","pred":"chebi_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/CHEBI_37926"}],"text":"Serum samples were collected from the index case on Days 4, 9, 10 and 20 from onset of the first symptoms (Figure 1). Presence of serum IgM and IgG antibodies against SARS-CoV-2 was analysed by immunofluorescence assays (IFA) based on Vero E6 cells infected with passage 4 of the patient’s isolate SARS-CoV-2/Finland/1/2020 virus and transferred onto microscope slides and fixed with acetone (Figure 2). Serum samples from the index case were serially diluted and incubated for 2 h for IgM and 30 min for IgG. Antibodies were visualised with fluorescein isothiocyanate (FITC)-conjugated anti-human IgM or IgG antibodies. While the antibodies were undetectable on Day 4 after onset of symptoms, IgG titres rose to 80 and 1,280 and IgM titres to 80 and 320 on Days 9 and 20, respectively (Table). Random serum samples from staff members of the University of Helsinki (n = 19) did not show specific binding at dilutions greater than 20 (Figure 2)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T62","span":{"begin":0,"end":117},"obj":"Sentence"},{"id":"T63","span":{"begin":118,"end":403},"obj":"Sentence"},{"id":"T64","span":{"begin":404,"end":509},"obj":"Sentence"},{"id":"T65","span":{"begin":510,"end":620},"obj":"Sentence"},{"id":"T66","span":{"begin":621,"end":794},"obj":"Sentence"},{"id":"T67","span":{"begin":795,"end":944},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Serum samples were collected from the index case on Days 4, 9, 10 and 20 from onset of the first symptoms (Figure 1). Presence of serum IgM and IgG antibodies against SARS-CoV-2 was analysed by immunofluorescence assays (IFA) based on Vero E6 cells infected with passage 4 of the patient’s isolate SARS-CoV-2/Finland/1/2020 virus and transferred onto microscope slides and fixed with acetone (Figure 2). Serum samples from the index case were serially diluted and incubated for 2 h for IgM and 30 min for IgG. Antibodies were visualised with fluorescein isothiocyanate (FITC)-conjugated anti-human IgM or IgG antibodies. While the antibodies were undetectable on Day 4 after onset of symptoms, IgG titres rose to 80 and 1,280 and IgM titres to 80 and 320 on Days 9 and 20, respectively (Table). Random serum samples from staff members of the University of Helsinki (n = 19) did not show specific binding at dilutions greater than 20 (Figure 2)."}